论文部分内容阅读
目的探讨不同剂量米非司酮对子宫内膜增生的临床治疗效果。方法对医院在2008年1月-2012年1月收治的80例子宫内膜增生患者的临床资料进行回顾性分析,随机分成照组和试验组各40例,对照组每天口服米非司酮10mg,试验组每天口服米非司酮25mg,所有患者均诊断性刮宫的第7天开始服药,连续3个月,对其治疗效果进行综合分析。结果对照组患者和试验组患者在服药治疗期间均出现闭经,所有患者的贫血状况得到不同程度的改善;与服药治疗之前相比,试验组患者的内膜转化率为100.0%,对照组患者内膜转化率为97.5%,差异无统计学意义(P>0.05)。结论每天服用米非司酮10mg用于治疗子宫内膜增生有着显著的效果,并且不良反应较低,值得在临床大力推广。
Objective To investigate the clinical effects of different doses of mifepristone on endometrial hyperplasia. Methods The clinical data of 80 patients with endometrial hyperplasia admitted in our hospital from January 2008 to January 2012 were retrospectively analyzed. They were randomly divided into the control group and the test group, 40 cases each. Mifepristone 10 mg , The experimental group oral mifepristone 25mg, all patients were diagnosed curettage on the 7th day of medication, for 3 consecutive months, the comprehensive analysis of the treatment effect. Results The patients in control group and test group all had amenorrhea during the course of medication, and the anemia of all patients was improved to some extent. Compared with those before treatment, the rate of endometrial conversion was 100.0% in test group and in control group Membrane conversion was 97.5%, with no significant difference (P> 0.05). Conclusion Taking mifepristone 10mg daily for the treatment of endometrial hyperplasia has a significant effect, and the adverse reactions are low, so it is worth to be vigorously promoted in clinic.